320 related articles for article (PubMed ID: 11502459)
21. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE.
Downs TM; Sadetsky N; Pasta DJ; Grossfeld GD; Kane CJ; Mehta SS; Carroll PR; Lubeck DP
J Urol; 2003 Nov; 170(5):1822-7. PubMed ID: 14532784
[TBL] [Abstract][Full Text] [Related]
22. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE.
Lubeck DP; Litwin MS; Henning JM; Stoddard ML; Flanders SC; Carroll PR
Urology; 1999 Jan; 53(1):180-6. PubMed ID: 9886609
[TBL] [Abstract][Full Text] [Related]
23. Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract][Full Text] [Related]
24. Quality-of-life outcomes for men with prostate carcinoma detected by screening.
Smith DS; Carvalhal GF; Schneider K; Krygiel J; Yan Y; Catalona WJ
Cancer; 2000 Mar; 88(6):1454-63. PubMed ID: 10717630
[TBL] [Abstract][Full Text] [Related]
25. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite.
Kakehi Y; Takegami M; Suzukamo Y; Namiki S; Arai Y; Kamoto T; Ogawa O; Fukuhara S
J Urol; 2007 May; 177(5):1856-61. PubMed ID: 17437836
[TBL] [Abstract][Full Text] [Related]
26. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
27. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
[TBL] [Abstract][Full Text] [Related]
28. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
29. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor.
Hu JC; Elkin EP; Krupski TL; Gore J; Litwin MS
Cancer; 2006 Jul; 107(2):281-8. PubMed ID: 16779794
[TBL] [Abstract][Full Text] [Related]
30. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.
Sadetsky N; Greene K; Cooperberg MR; Hubbard A; Carroll PR; Satariano W
Cancer; 2011 Oct; 117(19):4406-13. PubMed ID: 21412760
[TBL] [Abstract][Full Text] [Related]
31. Responsiveness of the University of California-Los Angeles Prostate Cancer Index.
Bergman J; Saigal CS; Kwan L; Litwin MS
Urology; 2010 Jun; 75(6):1418-23. PubMed ID: 19589573
[TBL] [Abstract][Full Text] [Related]
32. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
33. Quality of life after treatment for localized prostate cancer: differences based on treatment modality.
Davis JW; Kuban DA; Lynch DF; Schellhammer PF
J Urol; 2001 Sep; 166(3):947-52. PubMed ID: 11490252
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
Jayadevappa R; Chhatre S; Whittington R; Bloom BS; Wein AJ; Malkowicz SB
BJU Int; 2006 May; 97(5):955-62. PubMed ID: 16643477
[TBL] [Abstract][Full Text] [Related]
35. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.
Litwin MS; Pasta DJ; Yu J; Stoddard ML; Flanders SC
J Urol; 2000 Dec; 164(6):1973-7. PubMed ID: 11061894
[TBL] [Abstract][Full Text] [Related]
36. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
Berge V; Thompson T; Blackman D
Scand J Urol Nephrol; 2007; 41(3):198-203. PubMed ID: 17469027
[TBL] [Abstract][Full Text] [Related]
37. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
38. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy.
Namiki S; Saito S; Tochigi T; Ioritani N; Terai A; Arai Y
Int J Urol; 2007 Mar; 14(3):186-91. PubMed ID: 17430252
[TBL] [Abstract][Full Text] [Related]
39. Predicting quality of life after radical prostatectomy: results from CaPSURE.
Hu JC; Elkin EP; Pasta DJ; Lubeck DP; Kattan MW; Carroll PR; Litwin MS
J Urol; 2004 Feb; 171(2 Pt 1):703-7; discussion 707-8. PubMed ID: 14713791
[TBL] [Abstract][Full Text] [Related]
40. Quality-of-life outcomes in men treated for localized prostate cancer.
Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Leach GE; Brook RH
JAMA; 1995 Jan; 273(2):129-35. PubMed ID: 7799493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
